Session Overview

Microphysiological systems (MPS) or ‘organ-on-a-chip’ devices are microfluidic devices capable of emulating human biology in vitro. Monolayer monocultures fail to consider the dynamic conditions within the body and are therefore not an accurate representation of the human body. They are often an unreliable prediction of the effect of a drug and therefore MPS aims to bridge the gap between current models and human physiology.

Session Chair: Dr Malcolm Wilkinson

CEO

(Kirkstall Ltd.)

In 2007, Malcolm became full time CEO of Kirkstall Ltd, a company now at the leading edge of 'Organ-on-a-chip' technology. Kirkstall delivers Quasi Vivo® cell culture systems to match the emerging needs of stem cell research, in-vitro toxicity screening and drug metabolism applications.

Quasi Vivo® is a commercially available milli-fluidic interconnected cell culture flow system to significantly increase the physiological relevance of your research, enabling you to generate more accurate models (Liver, Respiratory, Cardio, CNS, Skin, Gut etc.) and greatly improve confidence in the validity of your results.

 

 

 

What papers are we looking for?

We are looking for a wide variety of papers on this topic to provide an academic and industry perspective.

Topics of interest include:

Microphysiological systems: how individual organoids can be developed and then connected to form a physiologically relevant system.

Evidence that mature organoids give data that is clinically relevant and more predictive than animal models or current in vitro methods.

What instruments, assays or end points are appropriate for connected 3D in vitro systems.

Click here to submit a title and abstract 

Interested in presenting?

Get in touch via the below form and we will get back to you as soon as possible.





The Presenters

 

To be confirmed

To be confirmed

To be confirmed

To be confirmed

 

To be confirmed

 

 

To be confirmed

 

 

REGISTER NOW